Concepedia

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo, A. Bardia, F. Marmé, J. Cortés, P. Schmid, D. Loirat, Olivier Trédan, E.M. Ciruelos, F. Dalenc, P. Gomez Pardo,

Annals of Oncology · 2022 · 57 citations · 0 references

DOIFull text

Open access

Concepts